Virginia Macdonald1, Lawrence Mbuagbaw2,3, Michael R Jordan4,5,6,7, Bradley Mathers1, Sharon Jay1, Rachel Baggaley1, Annette Verster1, Silvia Bertagnolio1. 1. Department of HIV, Hepatitis, and Sexually Transmitted Diseases, World Health Organization, Geneva, Switzerland. 2. Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, ON, Canada. 3. Biostatistics Unit, Father Sean O'Sullivan Research Centre, St Joseph's Healthcare-Hamilton, Hamilton, ON, Canada. 4. Division of Geographic Medicine, Tufts Medical Center, Boston, MA, USA. 5. Department of Public Health and Community Medicine, Tufts University School of Medicine, Boston, MA, USA. 6. Tufts Center for Integrated Management of Antimicrobial Resistance (CIMAR), Boston, MA, USA. 7. Levy Center for Integrated Management of Antimicrobial Resistance (CIMAR), Boston, MA, USA.
Abstract
INTRODUCTION: WHO's 2019 report on HIV drug resistance (HIVDR) documents a high prevalence of pretreatment drug resistance (PDR) among populations initiating first-line antiretroviral therapy (ART) in low- and middle-income countries (LMIC). However, systematic evidence on the prevalence of PDR among key populations remains limited. We performed a systematic review to characterize levels of PDR in key population groups and compared them to levels of PDR in the "general population" across different geographical regions. METHODS: Ten electronic databases were searched for papers published until February 2019 that included predefined search terms. We included studies that reported the number of successfully tested genotypes and the number of genotypes with drug resistance mutations among antiretroviral therapy treatment naïve people, recently infected people, or people initiating first-line ART from key populations. To assess the prevalence of PDR for each key population, we pooled estimates using random-effects meta-analysis of proportions. Where possible, we computed the differences in the odds of PDR (any, and by drug class) present in each key population compared to the "general population". The I2 statistic (a measure of heterogeneity between studies) is reported. RESULTS AND DISCUSSION: A total of 332 datasets (from 218 studies) and 63,111 people with successful HIVDR genotyping were included in the analysis. The pooled prevalence estimate of any PDR was high among men who have sex with men (13.0%, 95% CI 11.0 to 14.0%, I2 = 93.19), sex workers (17.0%, 95% CI 6.0 - 32.0, I2 = 87.31%) and people in prisons (18.0%, 95% CI 11.0 to 25.0, I2 = 70.18%), but less so among people who inject drugs (7.0%, 95% CI 5.0 to 10.0, I2 = 90.23). Overall, men who have sex with men were more likely to carry any PDR compared to the "general population," a finding which was statistically significant (odds ratio (OR) 1.28, 95% CI 1.13 - 1.46, I2 48.9%). CONCLUSIONS: High prevalence of PDR found in key populations highlights the need to increase access to effective first-line HIV treatment. The low prevalence of nucleotide reverse transcriptase inhibitor (NRTI) PDR suggests that current WHO recommendations for pre-exposure prophylaxis (PrEP) regimens will remain effective and can be scaled up to prevent new HIV infections in high-risk groups.
INTRODUCTION: WHO's 2019 report on HIV drug resistance (HIVDR) documents a high prevalence of pretreatment drug resistance (PDR) among populations initiating first-line antiretroviral therapy (ART) in low- and middle-income countries (LMIC). However, systematic evidence on the prevalence of PDR among key populations remains limited. We performed a systematic review to characterize levels of PDR in key population groups and compared them to levels of PDR in the "general population" across different geographical regions. METHODS: Ten electronic databases were searched for papers published until February 2019 that included predefined search terms. We included studies that reported the number of successfully tested genotypes and the number of genotypes with drug resistance mutations among antiretroviral therapy treatment naïve people, recently infectedpeople, or people initiating first-line ART from key populations. To assess the prevalence of PDR for each key population, we pooled estimates using random-effects meta-analysis of proportions. Where possible, we computed the differences in the odds of PDR (any, and by drug class) present in each key population compared to the "general population". The I2 statistic (a measure of heterogeneity between studies) is reported. RESULTS AND DISCUSSION: A total of 332 datasets (from 218 studies) and 63,111 people with successful HIVDR genotyping were included in the analysis. The pooled prevalence estimate of any PDR was high among men who have sex with men (13.0%, 95% CI 11.0 to 14.0%, I2 = 93.19), sex workers (17.0%, 95% CI 6.0 - 32.0, I2 = 87.31%) and people in prisons (18.0%, 95% CI 11.0 to 25.0, I2 = 70.18%), but less so among people who inject drugs (7.0%, 95% CI 5.0 to 10.0, I2 = 90.23). Overall, men who have sex with men were more likely to carry any PDR compared to the "general population," a finding which was statistically significant (odds ratio (OR) 1.28, 95% CI 1.13 - 1.46, I2 48.9%). CONCLUSIONS: High prevalence of PDR found in key populations highlights the need to increase access to effective first-line HIV treatment. The low prevalence of nucleotide reverse transcriptase inhibitor (NRTI) PDR suggests that current WHO recommendations for pre-exposure prophylaxis (PrEP) regimens will remain effective and can be scaled up to prevent new HIV infections in high-risk groups.
Authors: Claire E Holland; Seni Kouanda; Marcel Lougué; Vincent Palokinam Pitche; Sheree Schwartz; Simplice Anato; Henri Gautier Ouedraogo; Jules Tchalla; Clarence S Yah; Laurent Kapesa; Sosthenes Ketende; Chris Beyrer; Stefan Baral Journal: Public Health Rep Date: 2016-11-14 Impact factor: 2.792
Authors: Kate Shannon; Anna-Louise Crago; Stefan D Baral; Linda-Gail Bekker; Deanna Kerrigan; Michele R Decker; Tonia Poteat; Andrea L Wirtz; Brian Weir; Marie-Claude Boily; Jenny Butler; Steffanie A Strathdee; Chris Beyrer Journal: Lancet Date: 2018-07-20 Impact factor: 79.321
Authors: Diane E Bennett; Ricardo J Camacho; Dan Otelea; Daniel R Kuritzkes; Hervé Fleury; Mark Kiuchi; Walid Heneine; Rami Kantor; Michael R Jordan; Jonathan M Schapiro; Anne-Mieke Vandamme; Paul Sandstrom; Charles A B Boucher; David van de Vijver; Soo-Yon Rhee; Tommy F Liu; Deenan Pillay; Robert W Shafer Journal: PLoS One Date: 2009-03-06 Impact factor: 3.240
Authors: Amanda D Castel; Daniel J Feaster; Wenze Tang; Sarah Willis; Heather Jordan; Kira Villamizar; Michael Kharfen; Michael A Kolber; Allan Rodriguez; Lisa R Metsch Journal: J Acquir Immune Defic Syndr Date: 2015-12-15 Impact factor: 3.731
Authors: Ana Wheelock; Andreas B Eisingerich; Gabriela B Gomez; Emily Gray; Mark R Dybul; Peter Piot Journal: BMJ Open Date: 2012-07-02 Impact factor: 2.692
Authors: Lawrence Mbuagbaw; Clémence Ongolo-Zogo; Olivia C Mendoza; Babalwa Zani; Frederick Morfaw; Agatha Nyambi; Annie Wang; Michel Kiflen; Hussein El-Kechen; Alvin Leenus; Mark Youssef; Nadia Rehman; Lucas Hermans; Virginia MacDonald; Silvia Bertagnolio Journal: BMC Med Res Methodol Date: 2021-04-19 Impact factor: 4.615
Authors: Urvi M Parikh; Kerri J Penrose; Amy L Heaps; Elias K Halvas; B Jay Goetz; Kelley C Gordon; Russell Hardesty; Rahil Sethi; William Schwarzmann; Daniel W Szydlo; Marla J Husnik; Uma Chandran; Thesla Palanee-Phillips; Jared M Baeten; John W Mellors Journal: J Int AIDS Soc Date: 2021-11 Impact factor: 6.707